Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia

Schizophrenia Research

Volumn 134, Issue 1, 2012, Pages 83-88

  Dickerson, Faith ^a   Stallings, Cassie ^a   Origoni, Andrea ^a   Vaughan, Crystal ^a   Khushalani, Sunil ^a   Yolken, Robert ^b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Cognitive; Herpes simplex virus type 1; Immune response; Inflammatory marker; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; VIRUS ANTIBODY;

ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; ANTIBODIES, VIRAL; C-REACTIVE PROTEIN; COGNITION DISORDERS; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA;

EID: 84155172155     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.10.003     Document Type: Article

References (38)

1. American Psychiatric Association, 1994. Diagnostic and statistical manual of mental health disorders (4th ed). Washington, D.C.: Author.
2. Azar M., Valentin E., Badaoui G., Kassab R., Sarkis A., Azar R.R. Comparison of the effects of combination atorvastatin (40mg)+ezetimibe (10mg) versus atorvastatin (40mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Am. J. Cardiol. 2011, 107(11):1571-1574.
3. Brown A.S. The environment and susceptibility to schizophrenia. Prog. Neurobiol. 2011, 93(1):23-58.
4. Buchanan R.W., Freedman R., Javitt D.C., Abi-Dargham A., Lieberman J.A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull. 2007, 33(5):1120-1130.
5. Caparros-Lefebvre D., Girard-Buttaz I., Reboul S., Lebert F., Cabaret M., Verier A., Steinling M., Pruvo J.P., Petit H. Cognitive and psychiatric impairment in herpes simplex virus encephalitis suggest involvement of the amygdalo-frontal pathways. J. Neurol. 1996, 243(3):248-256.
6. Cherpes T.L., Ashley R.L., Meyn L.A., Hillier S.L. Longitudinal reliability of focus glycoprotein G-based type-specific enzyme immunoassays for detection of herpes simplex virus types 1 and 2 in women. J. Clin. Microbiol. 2003, 41(2):671-674.
7. Daheshia M., Feldman L.T., Rouse B.T. Herpes simplex virus latency and the immune response. Curr. Opin. Microbiol. 1998, 1(4):430-435.
8. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Ruslanova I., Yolken R.H. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 2003, 60(5):466-472.
9. Dickerson F., Boronow J.J., Stallings C., Origoni A.E., Cole S.K., Yolken R.H. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the repeatable battery for the assessment of neuropsychological status. Psychiatry Res. 2004, 129(1):45-53. Nov 30.
10. Dickerson F.B., Stallings C., Origoni A., Sullens A., Boronow J., Yolken R. C-reactive protein is associated with cognitive impairment but not psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93(1-3):261-265.
11. Dimopoulos N., Piperi C., Salonicioti A., Mitropoulos P., Kallai E., Liappas I., Lea R.W., Kalofoutis A. Indices of low-grade chronic inflammation correlate with early cognitive deterioration in an elderly Greek population. Neurosci. Lett. 2006, 398(1-2):118-123.
12. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153(3):321-330.
13. Gunstad J., Bausserman L., Paul R.H., Tate D.F., Hoth K., Poppas A., Jefferson A.L., Cohen R.A. C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J. Clin. Neurosci. 2006, 13(5):540-546.
14. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
15. Hokkanen L., Launes J. Cognitive outcome in acute sporadic encephalitis. Neuropsychol. Rev. 2000, 10(3):151-167.
16. Jerome K.R., Ashley R.L. Herpes simplex virus and herpes B virus. Manual of Clinical Microbiology 2003, 1291-1303. ASM Press, Washington, D.C. 8th edition. P.R. Murray, E.J. Baron, J.H. Jorgensen, R.H. Yolken (Eds.).
17. Jones C. Herpes simplex virus type 1 and bovine herpesvirus 1 latency. Clin. Microbiol. Rev. 2003, 16(1):79-95.
18. Kapur N., Barker S., Burrows E.H., Ellison D., Brice J., Illis L.S., Scholey K., Colbourn C., Wilson B., Loates M. Herpes simplex encephalitis: long term magnetic resonance imaging and neuropsychological profile. J. Neurol. Neurosurg. Psychiatry 1994, 57(11):1334-1342.
19. Kay S.R. Positive and negative syndromes in schizophrenia: assessment and research 1991, Bruner/Mazel, New York.
20. Lowe G.D. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J. Thromb. Haemost. 2005, 3(8):1618-1627.
21. Muller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia: an integrative view. Ann. N. Y. Acad. Sci. 2000, 917:456-467.
22. Prasad K.M., Bamne M.N., Shirts B.H., Goradia D., Mannali V., Pancholi K.M., Xue B., McClain L., Yolken R.H., Keshavan M.S., Nimgaonkar V.L. Grey matter changes associated with host genetic variation and exposure to Herpes Simplex Virus 1 (HSV1) in first episode schizophrenia. Schizophr. Res. 2010, 118(1-3):232-239.
23. Ramlawi B., Rudolph J.L., Mieno S., Khabbaz K., Sodha N.R., Boodhwani M., Levkoff S.E., Marcantonio E.R., Sellke F.W. Serologic markers of brain injury and cognitive function after cardiopulmonary bypass. Ann. Surg. 2006, 244(4):593-601.
24. Randolph C. RBANS manual-Repeatable Battery for the Assessment of Neuropsychological Status 1998, Psychological Corporation (Harcourt), San Antonio, TX.
25. Ravaglia G., Forti P., Maioli F., Brunetti N., Martelli M., Servadei L., Bastagli L., Bianchin M., Mariani E. Serum C-reactive protein and cognitive function in healthy elderly Italian community dwellers. J. Gerontol. A Biol. Sci. Med. Sci. 2005, 60(8):1017-1021.
26. Regier D.A., Narrow W.E., Rae D.S., Manderscheid R.W., Locke B.Z., Goodwin F.K. The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch. Gen. Psychiatry 1993, 50(2):85-94.
27. Salonen E.M. A rapid and sensitive solid-phase enzyme immunoassay for C-reactive protein. J. Immunol. Methods 1982, 48(1):45-50.
28. Schretlen D.J., Winicki J.M., Mushtaq Y., Hikida T., Sawa A., Yolken R.H., Dickerson F.B., Cascella N.G. Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia. Schizophr. Res. 2010, 118(1-3):224-231.
29. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Rothermundt M., Bogerts B., Koethe D., Kranaster L., Ohrmann P., Suslow T., McAllister G., Spain M., Barnes A., van Beveren N.J., Baron-Cohen S., Steiner J., Torrey E.F., Yolken R.H., Bahn S. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2011, Apr 12. Epub ahead of print.
30. Shirts B.H., Prasad K.M., Pogue-Geile M.F., Dickerson F., Yolken R.H., Nimgaonkar V.L. Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia. Schizophr. Res. 2008, 106(2-3):268-274.
31. Taylor T.J., Brockman M.A., McNamee E.E., Knipe D.M. Herpes simplex virus. Front Biosci. 2002, 7:d752-d764.
32. Tiwari A.K., Zai C.C., Müller D.J., Kennedy J.L. Genetics in schizophrenia: where are we and what next?. Dialogues Clin. Neurosci. 2010, 12(3):289-303.
33. Vyse A.J., Gay N.J., Slomka M.J., Gopal R., Gibbs T., Morgan-Capner P., Brown D.W. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex. Transm. Infect. 2000, 76(3):183-187.
34. Whitley R.J., Gnann J.W. Viral encephalitis: familiar infections and emerging pathogens. Lancet 2002, 359(9305):507-513.
35. Wilk C.M., Gold J.M., Humber K., Dickerson F., Fenton W.S., Buchanan R.W. Brief cognitive assessment in schizophrenia: normative data for the repeatable battery for the assessment of neuropsychological status. Schizophr. Res. 2004, 70(2-3):175-186.
36. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 2011, 168(5):472-485.
37. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 1995, 8(1):1311-1345.
38. Yolken R.H., Torrey E.F., Lieberman J.A., Yang S., Dickerson F.B. Serological evidence of exposure to herpes simplex virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr. Res. 2011, 128(1-3):61-65.